← Back to patent-cliff list
Al18F-NOTA-Pentixafor
Tier C — Watch / tradeAl18F-NOTA-Pentixafor
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：CXCR4
Indications (approved)：醛固酮增多症
Regional status
US
-
EU
-
China
Phase II
2023-12-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Al18F-NOTA-Pentixafor?
Approved indications include: 醛固酮增多症.
When does the Al18F-NOTA-Pentixafor patent expire?
No public expiry year is available for Al18F-NOTA-Pentixafor yet; this page updates once verified.
How do I get a quote for Al18F-NOTA-Pentixafor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02